Complex management of type 2 heparin-induced thrombocytopenia in patients with major bleeding tendency: two case report
| Autor: | Valérie Proulle, Marie Werner, Sylvain Drouot, Orane Gleizes, Nicolas Legris, Olivier Chassin, Benjamin Bergis, Noémie Chanson, Eve-Marie Walle, Catherine Ract |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Vitamin K Hemorrhage Context (language use) Arginine Drug Administration Schedule Neurosurgical Procedures Argatroban Heparin-induced thrombocytopenia medicine Humans Platelet Refractory Thrombocytopenia Aged Sulfonamides Dose-Response Relationship Drug Heparin business.industry Anticoagulants 4-Hydroxycoumarins General Medicine Blood Coagulation Disorders Middle Aged medicine.disease Thrombocytopenia Thrombosis Indenes Pipecolic Acids Drug Therapy Combination Intracranial Thrombosis business Major bleeding medicine.drug |
| Zdroj: | Annales de Biologie Clinique. 78:639-646 |
| ISSN: | 0003-3898 |
| DOI: | 10.1684/abc.2020.1603 |
| Popis: | Type 2 heparin-induced thrombocytopenia (HIT 2) is a rare pro-thrombotic disorder occurring in patients treated with heparin. It is defined as a clinical-biological syndrome associating the sudden onset of a thrombocytopenia, characterized by a drop of more than 50% of the initial platelet count, and thrombosis. We report two cases of HIT 2 occurring in patients with major bleeding tendency. The first HIT occurred in a patient whose management, in accordance with current guidelines, made it possible to control the thrombocytopenia and the anticoagulation despite the complexity of adapting and monitoring treatments in the context of recent cerebral hemorrhage. The second refers to an autoimmune HIT, which occurred in a patient whose management required the use of alternative therapies to the standard treatments suggested for HIT 2, to correct the severe refractory thrombocytopenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|